We are monitoring the impact of COVID-19 on North America Cervical Cancer Diagnostics and Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 772
Share on
Share on

North America Cervical Cancer Diagnostics and Therapeutics Market Research Report - Segmented By Diagnostics Test, Methods, Therapies, End-users & By Country (United States, Canada & Rest of North America) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 772
Pages: 140

North America Cervical Cancer Diagnostics and Therapeutics Market Size (2021 to 2026)

The Cervical Cancer Diagnostics and Therapeutics Market size in North America is estimated to value USD 1604.88 million by 2026 from USD 1325.45 million in 2021, growing at a CAGR of 3.90% during the forecast period.  

The growth of the cervical cancer diagnostics and therapies market in North America is majorly driven by government initiatives supporting cervical cancer prevention, increasing prevalence of cervical cancer, raising awareness increased to early diagnosis, and strong R&D key players.

According to the World Health Organization (WHO), more than 270,500 women die from cervical cancer each year. The death rate from cervical cancer is higher in developing regions due to inadequate detection in the early stages of the disease. With the increasing adoption of cervical cancer diagnostic tests to detect cervical cancer, the market is expected to grow.

Increased awareness of the general population about the care, prevention, and treatment of cervical cancer, increased behaviors, such as sex with multiple partners and smoking, certain genetic factors, and a weakened immune system are linked to the growth of cervical cancer diagnostic and therapeutic market. In addition, factors such as the increasing prevalence of Human Papilloma Virus (HPV) infection in women and the deficiency of the HPV vaccine, which does not cover all types of HPV infections, are driving the market growth.

For example, In the US, a government's popular insurance program, Medicare, covers the Pap test, pelvic exam, and clinical breast exam for cervical cancer screening every two years. These programs have proven to be responsible for the growth of the overall market.

HPV home testing kits help women easily collect samples and get results independently without having to go to the lab for testing. Hence, companies are focusing on patient comfort, thereby providing better market growth opportunities in the region.

A clear lack of trained health professionals and a lack of awareness among the people to help achieve effective implementation of screening programs is expected to restrain the growth of the Cervical Cancer Diagnostics and Therapeutics Market in North America growth. In addition, the economic and social constraints in this region will be a major challenge for the major market players seeking to invest in this region, potentially hampering the growth of the North American cervical cancer diagnosis and therapeutics market.

This research report on the North America Cervical Cancer Diagnostics and Therapeutics Market is segmented and sub-segmented into the following categories.

By Diagnostics Test:

  • Pap Smear Test
  • HPV Testing
  • Colposcopy
  • Cervical Cancer Biopsy

By Methods:

  • Molecular Method
  • Cytopathological Method
  • Physical Method

By Therapies:

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Others

By End-users:

  • Hospitals
  • Laboratories
  • Independent Physicians
  • Clinics
  • Others

By Country:

  • United States
  • Canada
  • Rest of North America

Geographically, the large market share of the North American market was accounted for by the U.S. in 2020, and this can be attributed to the strong awareness of disease prevention among women in the region, as well as the many initiatives put in place to prevent cervical cancer, which has broadened the reach of insurance coverage for cervical screening, especially for people with low-income women.

The United States government contributes to the coverage and reimbursement of smears. The federal law was passed through the Affordable Care Act (ACA) to require coverage for cervical cancer screenings. Self-insurance plans also cover it.

There are also support programs like the National Cervical Cancer Early Detection and Program (NBCCEDP), which offers cervical cancer screenings to uninsured women free or at a meager cost. In addition, according to the Federal Advisory Committee on Immunization Practices (ACIP) recommendations, the U.S. government is attempting to include the HPV vaccine in insurance plans and include it in the Federal Childhood Immunization Program (VFC). All of these government initiatives for cervical cancer prevention have resulted in market growth.

KEY MARKET PLAYERS:

Companies playing a dominant role in the North America Cervical Cancer Diagnostics and Therapeutics market profiled in this report are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, EDP Biotech, Epigenomics AG, Exact Sciences, Fujirebio, Genomic Tree, Metabiomics, Oncocyte (Biotime), Quest Diagnostics, Randox Laboratories, Siemens Healthcare, Volition Rx.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By diagnostics test                 

                             5.1.1 Pap smear test     

                             5.1.2 HPV testing           

                             5.1.3 Colposcopy           

                             5.1.4 Cervical cancer biopsy      

              5.2 By methods                            

                             5.2.1 Molecular method             

                             5.2.2 Cytopathological method 

                             5.2.3 Physical method  

              5.3 By therapies                           

                             5.3.1 Surgery    

                             5.3.2 Radiation therapy

                             5.3.3 Chemotherapy     

                             5.3.4 Other therapies   

              5.4 By end-users                          

                             5.4.1 Hospitals 

                             5.4.2 Laboratories         

                             5.4.3 Independent physicians   

                             5.4.4 Clinics      

                             5.4.5 Other end-users  

6. Geographical Analysis                                         

                             6.1 Introduction             

                             6.2 United States           

                             6.3 Canada       

7. Pipeline Product Analysis                                    

              7.1 Overview                  

              7.2 Pipeline Development Landscape                   

              7.3 Molecular Targets in the Pipeline                   

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target    

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Abbott Diagnostics                

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Alere                          

              9.3 Beckman Coulter                   

              9.4 Clinical Genomics                  

              9.5 Companion Dx                       

              9.6 EDP Biotech              

              9.7 Epigenomics AG                     

              9.8 Exact Sciences                        

              9.9 Fujirebio                    

              9.10 Genomic Tree                      

              9.11 Metabiomics                        

              9.12 Siemens Healthcare                          

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  2. North America Cervical Cancer Diagnostics and Therapeutics Market, By Diagnostics test, From 2021 to 2026 (USD Million)
  3. North America Cervical Cancer Pap smear test Market, By Region, From 2021 to 2026 (USD Million)
  4. North America Cervical Cancer HPV testing Market, By Region, From 2021 to 2026 (USD Million)
  5. North America Cervical Cancer Colposcopy Market, By Region, From 2021 to 2026 (USD Million)
  6. North America Cervical cancer biopsy Market, By Region, From 2021 to 2026 (USD Million)
  7. North America Cervical Cancer Diagnostics and Therapeutics Market, By Methods, From 2021 to 2026 (USD Million)
  8. North America Molecular method Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  9. North America Cytopathological method Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  10. North America Physical method Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  11. North America Cervical Cancer Diagnostics and Therapeutics Market, By Therapies, From 2021 to 2026 (USD Million)
  12. North America Surgery Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  13. North America Radiation therapy Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  14. North America Chemotherapy Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  15. North America Other therapies Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  16. North America Cervical Cancer Diagnostics and Therapeutics Market, By End-users, From 2021 to 2026 (USD Million)
  17. North America Hospitals Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  18. North America Laboratories Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  19. North America Independent physicians Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  20. North America Clinics Cervical Cancer Diagnostics and Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  21. North America Other end-users Market, By Region, From 2021 to 2026 (USD Million)
  22. United States Cervical Cancer Diagnostics and Therapeutics Market, By Diagnostics test, From 2021 to 2026 (USD Million)
  23. United States Cervical Cancer Diagnostics and Therapeutics Market, By Methods, From 2021 to 2026 (USD Million)
  24. United States Cervical Cancer Diagnostics and Therapeutics Market, By Therapies, From 2021 to 2026 (USD Million)
  25. United States Cervical Cancer Diagnostics and Therapeutics Market, By End-users, From 2021 to 2026 (USD Million)
  26. Canada Cervical Cancer Diagnostics and Therapeutics Market, By Diagnostics test, From 2021 to 2026 (USD Million)
  27. Canada Cervical Cancer Diagnostics and Therapeutics Market, By Methods, From 2021 to 2026 (USD Million)
  28. Canada Cervical Cancer Diagnostics and Therapeutics Market, By Therapies, From 2021 to 2026 (USD Million)
  29. Canada Cervical Cancer Diagnostics and Therapeutics Market, By End-users, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample